$DRMA
Dermata Therapeutics Inc Stock $drma

$drma Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000165495424003501 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.603M	$1.085M	$3.972M
YoY Change	47.72%	31.89%	-1.28%
% of Gross Profit
Research & Development	$1.601M	$1.135M	$4.070M
YoY Change	34.22%	27.65%	-27.98%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$3.204M	$2.220M	$8.042M
YoY Change	40.65%	29.69%	42.31%
Operating Profit	-$3.204M		-$8.042M
YoY Change	40.65%		-16.88%
Interest Expense	$69.30K	$85.86K	$247.2K
YoY Change	84.6%	103.99%	288.89%
% of Operating Profit
Other Income/Expense, Net	$1.400M
YoY Change
Pretax Income	-$3.134M	-$2.134M	-$7.795M
YoY Change	39.91%	27.81%	-18.9%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.134M	-$2.134M	-$7.795M
YoY Change	39.91%	27.81%	-18.9%
Net Earnings / Revenue
Basic Earnings Per Share			-$2.67
Diluted Earnings Per Share	-$0.47	-$0.45	-$2.67
COMMON SHARES
Basic Shares Outstanding	6.661M shares	3.189M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.734M	$7.438M	$7.438M
YoY Change	-46.0%	19.18%	19.18%
Cash & Equivalents	$4.734M	$7.438M
Short-Term Investments
Other Short-Term Assets	$446.1K	$532.1K	$532.1K
YoY Change	-14.54%	-22.94%	-22.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.180M	$7.979M	$7.979M
YoY Change	-44.27%	14.89%	14.89%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	-$4.00	$4.00	$0.00
YoY Change	-20.0%	-300.0%
TOTAL ASSETS
Total Short-Term Assets	$5.180M	$7.979M	$7.979M
Total Long-Term Assets	-$4.00	$4.00	$0.00
Total Assets	$5.180M	$7.979M	$7.979M
YoY Change	-44.27%	14.89%	14.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$822.5K	$866.0K	$866.0K
YoY Change	66.89%	74.36%	74.36%
Accrued Expenses	$549.2K	$757.6K	$757.6K
YoY Change	-23.1%	77.87%	77.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.372M	$1.624M	$1.624M
YoY Change	13.65%	75.98%	75.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.372M	$1.624M	$1.624M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.372M	$1.624M	$1.624M
YoY Change	13.65%	75.98%	75.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.52M	-$53.39M
YoY Change	18.16%	17.1%
Common Stock	$666.00	$393.00
YoY Change	178.66%	-68.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.808M	$6.355M	$6.355M
YoY Change
Total Liabilities & Shareholders Equity	$5.180M	$7.979M	$7.979M
YoY Change	-44.27%	14.89%	14.89%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.134M	-$2.134M	-$7.795M
YoY Change	39.91%	27.81%	-18.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.704M	-$1.149M	-$6.409M
YoY Change	63.94%	-37.06%	-27.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.606M
YoY Change			77.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	1.956M	$7.606M
YoY Change	-100.0%		77.84%
NET CHANGE
Cash From Operating Activities	-$2.704M	-1.149M	-$6.409M
Cash From Investing Activities
Cash From Financing Activities	$0.00	1.956M	$7.606M
Net Change In Cash	-$2.704M	806.8K	$1.197M
YoY Change	-207.09%	-144.2%	-126.26%
FREE CASH FLOW
Cash From Operating Activities	-$2.704M	-$1.149M	-$6.409M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	437102	shares
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001853816
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	770115	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3930840	shares
CY2022	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6400000.0	usd
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	24106	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023	drma	Weighted Average Basic And Diluted Common Units Shares WeightedAverageBasicAndDilutedCommonUnitsShares	2924398	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40739
CY2023	dei	Entity Registrant Name EntityRegistrantName	DERMATA THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3218736
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3525 Del Mar Heights Rd.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	322
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	800-2543
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4800000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6660840	shares
CY2023	dei	Auditor Firm AuditorFirmId	659
CY2023	dei	Auditor Name AuditorName	Moss Adams LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3930840	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	770115	shares
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4069766	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5651041	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3972140	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4023445	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	8041906	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9674486	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8041906	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-9674486	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	247216	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	63573	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7794690	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9610913	usd
CY2023	drma	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-2.67
CY2022	drma	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-13.92
CY2022	drma	Weighted Average Basic And Diluted Common Units Shares WeightedAverageBasicAndDilutedCommonUnitsShares	690666	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10107104	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4276365	usd
CY2022	drma	Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount	287	usd
CY2022	drma	Issuance Of Restricted Stock Unit Awards Amount IssuanceOfRestrictedStockUnitAwardsAmount	166875	usd
CY2022	drma	Issuance Of Common Stock Upon Conversion Of Restricted Stock Units Amount IssuanceOfCommonStockUponConversionOfRestrictedStockUnitsAmount	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1082136	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9610913	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6021854	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5651668	usd
CY2023	drma	Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount	187	usd
CY2023	drma	Issuance Of Common Stock Upon Exercise Of Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockUponExerciseOfWarrantsNetOfIssuanceCostsAmount	1953957	usd
CY2023	drma	Settlement Of Fractional Shares Paid In Cash Amount SettlementOfFractionalSharesPaidInCashAmount	-40	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	522082	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7794690	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6355018	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7794690	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9610913	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	522082	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	930325	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-162695	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-121940	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	369326	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-18543	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	331656	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-256973	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1385759	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	776749	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6408931	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8834164	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7605625	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4276365	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	187	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	287	usd
CY2023	drma	Payment For Fractional Shares In Reverse Stock Split PaymentForFractionalSharesInReverseStockSplit	40	usd
CY2022	drma	Payment For Fractional Shares In Reverse Stock Split PaymentForFractionalSharesInReverseStockSplit	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7605772	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4276652	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1196841	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4557512	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6241294	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10798806	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7438135	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6241294	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	950	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	950	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	144765	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023	drma	Incremental Fair Value Of Warrant Inducement IncrementalFairValueOfWarrantInducement	2995343	usd
CY2022	drma	Incremental Fair Value Of Warrant Inducement IncrementalFairValueOfWarrantInducement	0	usd
CY2021Q3	drma	Class Of Warrant Or Right Exercise Price Of Warrants Or Right ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight	112.00
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	7400000	usd
CY2023Q4	drma	Accumulated Deficit AccumulatedDeficit	-53400000	usd
CY2023	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6400000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company is exposed to credit risk in the event of a default by the financial institutions holding the Company’s cash and cash equivalents to the extent of the amounts held in excess of FDIC limits. The Company limits its credit risk by placing its cash and cash equivalents with financial institutions it believes are of high quality. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7794690	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9610913	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.92
CY2023	drma	Weighted Average Number Of Basic And Diluted Shares Outstanding WeightedAverageNumberOfBasicAndDilutedSharesOutstanding	2924398	shares
CY2022	drma	Weighted Average Number Of Basic And Diluted Shares Outstanding WeightedAverageNumberOfBasicAndDilutedSharesOutstanding	690666	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8460771	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	503085	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	drma	Warrants To Purchase Up To Shares Of Common Stock WarrantsToPurchaseUpToSharesOfCommonStock	3472095	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.82
CY2023Q4	drma	Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights	0.6511
CY2024Q1	drma	Received Net Cash Proceeds ReceivedNetCashProceeds	2000000.0	usd
CY2024Q1	drma	Offering Expenses OfferingExpenses	300000	usd
CY2023Q2	drma	Proceeds Cash From Pipe ProceedsCashFromPipe	1500000	usd
CY2023Q2	drma	Underwriters Discounts And Offering Expenses In Pipe UnderwritersDiscountsAndOfferingExpensesInPipe	300000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2023	drma	Description Of Abeyance Shares DescriptionOfAbeyanceShares	the Holder left 2,730,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request. The 2,730,000 shares held in abeyance were delivered to the Holder on January 8, 2024. Accordingly, as of December 31, 2023, 2,730,000 shares were held in abeyance, have not been issued and are not outstanding
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8358697	shares
CY2023	drma	Warrant Reduced Description WarrantReducedDescription	from $21.20 to $2.82 per share upon closing of the March 2023 Offering
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1637000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2018000	usd
CY2023	drma	Income Tax Reconciliation Permanent And Other Difference IncomeTaxReconciliationPermanentAndOtherDifference	55000	usd
CY2022	drma	Income Tax Reconciliation Permanent And Other Difference IncomeTaxReconciliationPermanentAndOtherDifference	68000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	86000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	89000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-259000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-219000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1755000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2080000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2980000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1927000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	596000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	337000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1508000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1068000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	311000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	49000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	129000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5464000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3709000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5464000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3709000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	drma	Valuation Allowance ValuationAllowance	5500000	usd
CY2022Q4	drma	Valuation Allowance ValuationAllowance	37000	usd
CY2021Q4	drma	Valuation Allowance ValuationAllowance	1800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	14200000	usd
CY2023Q4	drma	Net Operating Loss Carryforwards Taxable Income Offset Limit Percentage NetOperatingLossCarryforwardsTaxableIncomeOffsetLimitPercentage	0.80	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	557000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	41000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	64000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	81000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	24000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	435000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	645000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	557000	usd
CY2023Q4	us-gaap	Shares Outstanding SharesOutstanding	101465	shares
CY2023Q4	us-gaap	Common Unit Authorized CommonUnitAuthorized	102074	shares

Files In Submission

Name	View Source	Status
0001654954-24-003501-index-headers.html	Edgar Link	pending
0001654954-24-003501-index.html	Edgar Link	pending
0001654954-24-003501.txt	Edgar Link	pending
0001654954-24-003501-xbrl.zip	Edgar Link	pending
drma-20231231.xsd	Edgar Link	pending
drma_10k.htm	Edgar Link	pending
drma_10kimg1.jpg	Edgar Link	pending
drma_10kimg10.jpg	Edgar Link	pending
drma_10kimg11.jpg	Edgar Link	pending
drma_10kimg12.jpg	Edgar Link	pending
drma_10kimg2.jpg	Edgar Link	pending
drma_10kimg3.jpg	Edgar Link	pending
drma_10kimg4.jpg	Edgar Link	pending
drma_10kimg5.jpg	Edgar Link	pending
drma_10kimg6.jpg	Edgar Link	pending
drma_10kimg8.jpg	Edgar Link	pending
drma_ex231.htm	Edgar Link	pending
drma_ex232.htm	Edgar Link	pending
drma_ex311.htm	Edgar Link	pending
drma_ex312.htm	Edgar Link	pending
drma_ex321.htm	Edgar Link	pending
drma_ex412.htm	Edgar Link	pending
drma_ex971.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
drma-20231231_def.xml	Edgar Link	unprocessable
drma-20231231_lab.xml	Edgar Link	unprocessable
drma-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
drma_10k_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
drma-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRMA
Dermata Therapeutics Inc Stock $drma

2024 Q1 Form 10-K Financial Statement

#000165495424003501 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRMA Dermata Therapeutics Inc Stock $drma

2024 Q1 Form 10-K Financial Statement

#000165495424003501 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRMA
Dermata Therapeutics Inc Stock $drma